Marc Banjak
Vermögen: 31 750 $ am 31.08.2026
Vermögen: 31 750 $ am 31.08.2026
Mr. Marc A. Banjak is a Chief Legal Officer at iBio, Inc. Mr. Banjak was previously employed as a General Counsel by Dova Pharmaceuticals, Inc., a General Counsel by Istari Oncology, Inc., and a Member by The Colorado Bar Association.
He received his undergraduate degree from Franklin & Marshall College and a graduate degree from Sturm College of Law.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IBIO, INC. 0.07% | 01.09.2026 | 25’000 ( 0.07% ) | 31 750 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| IBIO, INC. | General Counsel | - |
| Unternehmen | Position | Ende |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | General Counsel | 01.04.2021 |
The Colorado Bar Association | Corporate Officer/Principal | - |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Comptroller/Controller/Auditor | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Colorado Bar Association | |
iBio, Inc.
iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins | Health Technology |
Sturm College of Law
Sturm College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs with disorder of low blood platelet count | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology that focused on novel immuno-oncology and immunotherapy products | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen